Celularity Announces Closing of Transaction with NexGel
Rhea-AI Summary
Celularity (Nasdaq: CELU) closed a transaction with NexGel on April 21, 2026, selling certain commercial and other assets from its biomaterials product portfolio.
Celularity received $13.3 million consideration: $8.3M cash at closing and a $5.0M convertible promissory note, plus up to $20.0M in milestone payments and royalties. The deal enabled retirement of nearly $13.0M of debt and aims to refocus resources on Celularity’s longevity therapeutic pipeline and manufacturing platform.
AI-generated analysis. Not financial advice.
Positive
- Upfront consideration of $13.3M received
- Potential additional $20.0M in milestone payments
- Retired nearly $13.0M of debt
- Preserves royalty upside on licensed development-stage products
Negative
- Upfront cash was $8.3M, with material upside contingent
- Received $5.0M convertible note rather than all cash
- Direct commercial control of sold biomaterials assets transferred to NexGel
News Market Reaction – CELU
On the day this news was published, CELU declined 1.61%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $613K from the company's valuation, bringing the market cap to $37.49M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves appear mixed, with names like ANL up 3.92% and ALXO down 2.86%. With no clear, broad biotech trend and CELU only modestly higher, the reaction looks company-specific to this NexGel transaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Partnership reiteration | Positive | -0.8% | Reiterated commercialization partnership with NEXGEL and expected closing timeline. |
| Mar 10 | License deal | Positive | +11.2% | Exclusive biomaterials license with up to $35M plus future royalties. |
| Feb 10 | NOL sale proceeds | Positive | -2.3% | Received $12.2M non-dilutive cash from NJ NOL and R&D credit sales. |
| Dec 26 | Reimbursement update | Positive | +1.5% | CMS withdrawal of LCDs left Medicare rates intact and removed many competitors. |
| Dec 22 | Financing closed | Neutral | -2.3% | Closed $10M financing with additional $2M potential via term loan and convertibles. |
Capital-raising and strategic monetization headlines have produced mixed reactions, with several positive liquidity events followed by short-term share price declines.
Over the past few months, Celularity has focused on liquidity and strategic realignment. On Dec 22, 2025, it closed financing transactions totaling up to $12.0M. In February 2026, it generated $12.2M of non-dilutive cash from New Jersey NOL and R&D credit sales. In March, it announced a strategic biomaterials license with up to $35M in upfront and milestone payments and reiterated a commercialization partnership with NEXGEL. Today’s closing of the NexGel asset and license transaction fits this ongoing effort to monetize biomaterials while refocusing on longevity therapeutics.
Market Pulse Summary
This announcement closes the previously outlined NexGel transaction, delivering $13.3M in consideration, including $8.3M in cash and a $5.0M convertible note, and allowing retirement of nearly $13.0M of debt. It continues Celularity’s recent pattern of monetizing assets and securing non-dilutive or structured funding. Investors may watch how this affects cash runway, execution of the longevity-focused pipeline, and realization of up to $20.0M in potential milestones and future royalties.
Key Terms
convertible promissory note financial
milestone payments financial
royalties financial
AI-generated analysis. Not financial advice.
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (“NexGel”), pursuant to which NexGel acquired certain commercial and other assets related to Celularity’s biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity’s biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform.
Under the terms of the transaction, Celularity received aggregate consideration of
“This transaction with NexGel marks an important step in Celularity’s ongoing efforts to sharpen strategic focus, monetize non-core biomaterials assets and strengthen Celularity’s capital position as we advance our longevity-focused strategy,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Founder, Chairman and Chief Executive Officer. “By streamlining our biomaterials activities while retaining the opportunity to participate in future milestone and royalty economics, we are further aligning resources around high-value cellular therapeutics and other programs targeting the fundamental mechanisms of aging.”
About Celularity
Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.
For more information, please visit www.celularity.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expected benefits of the transaction with NexGel, Celularity’s ability to receive future royalty and milestone payments, the anticipated balance sheet and capital position benefits of the transaction, and Celularity’s strategic plans, including its longevity-focused strategy, and Celularity’s ability to realize the anticipated strategic and financial benefits of the transaction. These forward-looking statements are based on current beliefs, expectations and assumptions and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to NexGel’s commercialization of the licensed products, the achievement of royalty and milestone thresholds, and other risks and uncertainties described in Celularity’s filings with the Securities and Exchange Commission. Celularity undertakes no obligation to update any forward-looking statements except as required by law.
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
